Pediatric Hereditary Cancer Clinic
The UCSF Pediatric Hereditary Cancer Clinic cares for children and families with genetic mutations that increase their risk for cancer.
Our services include:
- Genetic counseling and testing for patients and their families
- Personalized recommendations for long-term monitoring based on genetic test results and family history
- Coordination of follow-up care, including cancer prevention and monitoring, with referrals to other UCSF specialty clinics, as needed
This clinic is part of the UCSF Pediatric Cancer Program. Our team of providers includes genetic counselors and pediatric oncologists, as well as a medical geneticist (a doctor who specializes in care for genetic disorders), nurse coordinator and patient navigator. We are dedicated to meeting the unique needs of families who carry mutations linked to hereditary cancers, including by helping them navigate both the psychological and the medical aspects of having an increased cancer risk.
What to expect
If previous genetic testing has shown that your child carries a mutation associated with hereditary cancer, our team will review the findings, talk to you about recent medical research related to your situation, and describe current recommendations for cancer monitoring and prevention. Your child's provider will conduct a physical exam and ask questions to better understand the medical history, including details on the birthing parent's pregnancy and the child's birth and early development. We may recommend additional screening exams or consultations with other specialists.
If your child hasn't had genetic testing, we will review the medical records, collect details on your family health history and give you information on hereditary cancer. We can help you weigh the potential benefits and limitations of testing as you decide whether it's right for your family.
For genetic testing, we typically swab the inside of the cheek or collect a blood sample, then send it to a specialized laboratory where it's tested for mutations associated with a higher chance of developing specific cancers. In some cases, your genetic counselor may recommend additional testing for your child or offer genetic testing to other family members.
As the scientific understanding of hereditary cancer improves, our knowledge and recommendations continue to evolve. We invite each of our patients to enroll in a long-term study that uses your information anonymously in research on hereditary cancer. As part of this study, we will periodically send you updates on relevant advances and also request occasional updates about your family. Our team can tell you more about this and other research opportunities during your appointment.
Before your appointment
We will email you a link to a family history questionnaire or, if you prefer, mail you a paper copy. Please complete the questionnaire before your appointment.
Please send us a copy of the results of any previously performed genetic testing for your child or biologically related family members. If you have difficulty getting the original lab reports, contact our office for assistance.
Our locations (1)
Awards & recognition
-
Best in Northern California for cancer care
-
Ranked among the nation's best in 11 specialties
Plan your visit
What to Bring
- Photo I.D.
- Health insurance card
- Insurance authorization, if required
- Doctor's referral, if required
- Recent test results related to your child's condition
- List of medications, including dosages, plus any your child is allergic to
- List of questions you may have
- Device or paper for taking notes
Related clinics (4)
Support services
Clinical trials
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
To measure the response of treatments chosen based on: • Event free survival (EFS)
Recruiting
More about this study
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
To evaluate the efficacy of difluoromethylornithine (DFMO) in combination with etoposide in patients with relapsed/refractory neuroblastoma, based upon: o Event free survival (EFS) from time of enrollment.
Recruiting
More about this study
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Measured by the presence of radiologically assessable disease by cross-sectional computed tomography (CT) or Magnetic resonance imaging (MRI) imaging and/or by metaiodobenzylguanidine (MIBG) or positron emission tomography (PET) s...
Recruiting
More about this study
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarco...
Estimated four year thoracic event free survival (tEFS) where tEFS is calculated as the time from study enrollment. Any recurrence within the pulmonary parenchyma, involving the pleural surface or the drain/surgical site wound wil...
Recruiting
More about this study
Project: Every Child for Younger Patients With Cancer
The number of patients who agree to be in the Biobanking part of the study and have leftover tumor tissue and some normal blood, bone marrow, or other tissue saved for future research.
Recruiting
More about this study
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Adva...
Will be estimated over time and considered in relationship to changes in treatment trial cohort status (activations, suspensions, terminations).
Recruiting
More about this study
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusi...
The Kaplan-Meier method will be used to estimate 3-year FFS along with 80% log-minus-log transformed confidence limits for very low risk (VLR) patients.
Recruiting
More about this study
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Child...
EFS time is calculated from time of randomization to Arms A or B to first episode of disease relapse or progression, second malignancy, or death, or until last contact if no event has occurred.
Recruiting
More about this study
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
o To evaluate the efficacy of difluoromethylornithine (DFMO) as a single agent in preventing relapse in patients with molecular high risk and very high risk medulloblastoma, and relapsed/refractory medulloblastoma based upon the 2...
Recruiting
More about this studyTender wagging care
Our therapy dogs spread joy and smiles at the bedside and throughout the hospital.
Visit Child Life services